These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 17403126

  • 1. A randomized controlled trial examining combinations of repaglinide, metformin and NPH insulin.
    Davies MJ, Thaware PK, Tringham JR, Howe J, Jarvis J, Johnston V, Kitchener DL, Skinner TC, McNally PG, Lawrence IG.
    Diabet Med; 2007 Jul; 24(7):714-9. PubMed ID: 17403126
    [Abstract] [Full Text] [Related]

  • 2. Combination-therapy with bedtime nph insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes.
    Olsson PO, Lindström T.
    Diabetes Metab; 2002 Sep; 28(4 Pt 1):272-7. PubMed ID: 12442064
    [Abstract] [Full Text] [Related]

  • 3. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M.
    Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
    [Abstract] [Full Text] [Related]

  • 4. Repaglinide in combination therapy.
    Moses R.
    Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):33-8. PubMed ID: 12702006
    [Abstract] [Full Text] [Related]

  • 5. Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.
    Raskin P.
    Diabetes Obes Metab; 2008 Dec; 10(12):1167-77. PubMed ID: 18494804
    [Abstract] [Full Text] [Related]

  • 6. The combination oral and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial results.
    Reboussin DM, Goff DC, Lipkin EW, Herrington DM, Summerson J, Steffes M, Crouse RJ, Jovanovic L, Feinglos MN, Probstfield JL, Banerji MA, Pettitt DJ, Williamson J.
    Diabet Med; 2004 Oct; 21(10):1082-9. PubMed ID: 15384954
    [Abstract] [Full Text] [Related]

  • 7. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
    Ceriello A, Del Prato S, Bue-Valleskey J, Beattie S, Gates J, de la Peña A, Malone J.
    J Diabetes Complications; 2007 Oct; 21(1):20-7. PubMed ID: 17189870
    [Abstract] [Full Text] [Related]

  • 8. Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus.
    Shapiro MS, Abrams Z, Lieberman N.
    Isr Med Assoc J; 2005 Feb; 7(2):75-7. PubMed ID: 15729954
    [Abstract] [Full Text] [Related]

  • 9. Continuing metformin when starting insulin in patients with Type 2 diabetes: a double-blind randomized placebo-controlled trial.
    Douek IF, Allen SE, Ewings P, Gale EA, Bingley PJ, Metformin Trial Group.
    Diabet Med; 2005 May; 22(5):634-40. PubMed ID: 15842521
    [Abstract] [Full Text] [Related]

  • 10. Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study.
    De Mattia G, Laurenti O, Moretti A.
    Acta Diabetol; 2009 Mar; 46(1):67-73. PubMed ID: 19030772
    [Abstract] [Full Text] [Related]

  • 11. Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents.
    Furlong NJ, Hulme SA, O'Brien SV, Hardy KJ.
    Diabet Med; 2003 Nov; 20(11):935-41. PubMed ID: 14632720
    [Abstract] [Full Text] [Related]

  • 12. [Comparison on efficacy and safety of two regimens for treatment of type 2 diabetes mellitus: glargine plus metformin versus neutral protamine hagedorn plus metformin].
    Hu M, Luo Y, Zhang L, Yang X, Zhang H.
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2010 Jun; 27(3):622-5. PubMed ID: 20649032
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group.
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials.
    Bazzano LA, Lee LJ, Shi L, Reynolds K, Jackson JA, Fonseca V.
    Diabet Med; 2008 Aug; 25(8):924-32. PubMed ID: 18959605
    [Abstract] [Full Text] [Related]

  • 15. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
    Clements MR, Tits J, Kinsley BT, Råstam J, Friberg HH, Ligthelm RJ.
    Diabetes Obes Metab; 2008 Mar; 10(3):229-37. PubMed ID: 18269638
    [Abstract] [Full Text] [Related]

  • 16. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
    Hassan K, Rodriguez LM, Johnson SE, Tadlock S, Heptulla RA.
    Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
    [Abstract] [Full Text] [Related]

  • 17. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
    Hermansen K, Dornhorst A, Sreenan S.
    Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
    [Abstract] [Full Text] [Related]

  • 18. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs.
    Yang W, Ji Q, Zhu D, Yang J, Chen L, Liu Z, Yu D, Yan L.
    Diabetes Care; 2008 May; 31(5):852-6. PubMed ID: 18268073
    [Abstract] [Full Text] [Related]

  • 19. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study.
    Gao Y, Guo XH, Vaz JA, PRESENT Study Group.
    Diabetes Obes Metab; 2009 Jan; 11(1):33-40. PubMed ID: 18494806
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of once- or twice-daily extended release metformin compared with thrice-daily immediate release metformin in type 2 diabetes mellitus.
    Bhansali A, Masoodi SR.
    J Assoc Physicians India; 2005 May; 53():441-5. PubMed ID: 16124352
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.